New horizons for autoimmune hyperthyroidism with FcRn blockers

Area of Science:

• Endocrinology
• Immunology
• Pharmacology

Background:

• Autoimmune hyperthyroidism, including Graves' disease and thyroid eye disease, presents significant clinical challenges.
• Advances in neonatal Fc receptor (FcRn) biology offer new therapeutic targets.

Purpose of the Study:

• To review emerging literature on FcRn blockers Batoclimab, Imeroprubart, and Efgartigimod for Graves' disease and thyroid eye disease.
• To evaluate the efficacy and safety of these novel immunomodulatory agents.

Main Methods:

• Review of preliminary Phase 2 and Phase 3 clinical trial data.
• Analysis of case reports and ongoing clinical trial results.

Main Results:

• Batoclimab demonstrated rapid normalization of thyroid hormone levels and reduction in anti-TSH receptor antibodies in Graves' disease patients.
• A subset of patients achieved sustained seroconversion with Batoclimab, with one case reporting long-term remission.
• Efgartigimod Phase 3 trials for thyroid eye disease were terminated early due to insufficient efficacy; ongoing trials for Imeroprubart and Batoclimab continue.

Conclusions:

• FcRn blockade represents a promising therapeutic strategy for autoimmune hyperthyroidism.
• Key factors such as treatment durability, cost-effectiveness, and optimal patient selection require further investigation.